Vericel Corp
NASDAQ:VCEL
| Market Cap (Intraday) | 2.23B |
| Current PE | 2,825.44 |
| Forward PE | 433.6 |
| 2yr Forward PE | 83.38 |
| 10-Day MA | $42.90 |
| 50-Day MA | $46.58 |
| 200-Day MA | $45.69 |
Vericel Corp Stock, NASDAQ:VCEL
64 Sidney Street, Cambridge, Massachusetts 02139-4170
United States of America
Phone: +1.617.588.5555
Number of Employees: 314
Description
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.